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Abstract 
Deficits in Reelin expression and signaling play a pathogenic role in Alzheimer’s 
disease (AD). Thus, strategies aimed at correcting Reelin deficits may provide a novel 
therapeutic approach to treating AD. The cysteine-rich, whey protein supplement, 
Immunocal®, has recently been shown to rescue Reelin expression in a mouse model of 
Schizophrenia. Given that Reelin-expressing neurons of the entorhinal cortex region are 
a highly vulnerable population of cells that are lost early in AD, we examined the effects 
of Immunocal® in the hippocampal-entorhinal cortex formation in a mouse model of AD. 
Glutathione levels and Reelin expression in the hippocampal-entorhinal cortex formation 
(entorhinal cortex, EC; dentate gyrus, DG; and Cornu Ammonis, CA1/ Cornu Ammonis, 
CA3 regions of hippocampus) of 12-month old hAPPSweInd mice were significantly reduced 
when compared to non-carrier controls as measured by HPLC, western blot and 
immunohistochemistry respectively. These reductions were prevented in hAPPSweInd mice 
when treated with Immunocal® from 3 month to 12-month-old. We assessed the transcript 
levels of Reelin using in situ hybridization and show a reduction in Reelin transcript levels 
in untreated hAPPSweInd mice compared to non-carrier mice; However, Immunocal® 
treatment preserved Reelin transcript levels. Elevating Reelin expression through 
treatment with Immunocal® significantly reduced the number, size and density of Amylo-
glo stained amyloid plaques throughout the hippocampal-entorhinal cortex formation. Our 
findings demonstrate that Immunocal® rescues Reelin expression in vivo within the 
hippocampal-entorhinal cortex formation of 12-month-old transgenic hAPPSweInd mice. This 
rescue of Reelin expression was associated with an amelioration of the pathological 
amyloid plaque load. To our knowledge, these data provide the first evidence of a 
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therapeutic agent that is capable of correcting Reelin deficits in the hAPPSweInd mouse 
model of AD. Our findings support the testing of Immunocal® as a novel therapeutic agent 
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Chapter One: Introduction 
1.01 Aging and neurodegenerative diseases 
Aging is a natural progression of bio-molecular decay that occurs due to entropic 
events (DiLoreto et al. 2015).  This wear and tear originate from cells and eventually 
translates as a loss of function into tissues and organs. Cellular in-house repair and 
replacement processes maintain homeostasis such that functional molecules are retained. 
However, at the cost of reformation some by-products released are often deleterious and 
non-specific to target. Thereby its effects emerge at a later stage, creating a large 
asymptomatic period. Consequently, a misbalance in degradation of cellular debris and 
repair cycle ensues which ultimately results in Age-Related Diseases (ARD). There are 
several diseases such as cardiovascular, diabetes, neurological diseases that have a time 
dependency onset. Neurodegenerative diseases make a unique study under ARD since 
they are elusive in the field of research creating a large rate limiting step towards 
therapeutics. 
 Neurodegenerative diseases are a cohort of disorders that cause loss of structure 
and function in the central and peripheral nervous systems. One of the challenging 
aspects in this field is drug delivery. This is due to the presence of a blood brain barrier 
which acts as a molecular sieve wherein selectivity is based on polarity and size. Another 
complexity of these systems are the maintenance of synapses which assist in 
transmission of cellular and electrical signaling. Neuronal cells are more susceptible to 
aging diseases due to lack of regeneration capability once they are terminally 
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differentiated. Hence, any disruption in synaptic connections that may be the result of 
deficits in protein synthesis can lead to neuronal death. In order to address these 
challenges, there is a dire need to understand fundamental processes that are involved in 
building and maintaining neuronal connections. Alzheimer’s disease is one such disease 
that is a representation of neurodegeneration along the aging process. It currently requires 
attention due to a growing elderly population that are vulnerable to this form of dementia.  
1.02 Prevalence of Alzheimer’s disease 
Alzheimer’s disease (AD) is a chronic illness that is clinically characterized by 
dementia, behavioral impairment and socio-occupational dysfunction. Dementia is a 
syndrome that arises due to number of causes and its phenotypic presentation often 
depends on the severity and area of neuronal degradation. Its typical symptoms present 
as loss of memory and slow decline of other cognitive functions that affect a person’s 
ability to perform daily activities. As the disease progresses, other areas of the brain begin 
to degrade that are involved in controlling involuntary activities, making it fatal (Wilson et 
al. 2012) 
Several statistical studies have estimated that approximately 17% of people in the 
USA between the ages of 75-84 years-old have AD. Due to the nature of AD as being a 
slow and prolonged debilitating disease, patients often require full attention within 
caregiver facilities. This has led to greater costs which are estimated at about 236 billion 
dollars per year. It has been projected that the costs will triple by year 2050. According to 
the Alzheimer’s Association, approximately 13% of people over age 65 have AD and 45% 
of people over the age of 85 have AD. Due to a better healthcare system overall, there is 
a larger demographic shift in the population leading to longer lives. Hence it has been 
predicted that more people may be susceptible to having AD. Based on this predictive 
analysis, about 7.7 million people are projected to have AD and this number is expected 
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to double by 2050. AD is the sixth most common cause of death with over 5 million patients 
currently diagnosed in the United States and approximately 500,000 new cases each year 
(2017 Alzheimer's disease facts and figures). 
1.03 Pathology of Alzheimer’s disease and drug interventions 
Alzheimer’s disease was first described in 1906 by Dr. Alois Alzheimer and is 
characterized phenotypically by progressive memory loss and cognitive decline (Hanns 
Hippius, 2003). Pathological hallmarks of the disease include amyloid plaques consisting 
of insoluble deposits of amyloid beta (A) peptide and neurofibrillary tangles containing 
hyper-phosphorylated tau protein (Fig 1.) (L.Muche, 2009). These plaques and tangles 
are found throughout the brain parenchyma and are believed to play a significant role in 
the neuronal loss and atrophy that are characteristic of the AD brain. Of the diverse 
neuronal cell types that die in AD, hippocampal pyramidal cells, cortical pyramidal cells, 
and basal forebrain cholinergic neurons are among the most severely affected. The death 
of these populations of neurons leads to profound synaptic loss and significant 
neurotransmitter deficits, particularly in cholinergic pathways (Del Turco, D. et al. 2016) 
Although 3 genes (amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 
(PS2)) have been shown to be mutated in early onset, autosomal dominant, familial AD, 
these inherited forms of the disease make up less than 5% of AD cases, with the remaining 
95% of cases being sporadic in nature (Cacace, R. et al. 2016). 








        Figure 1: Cellular events of AD pathology (Figure adapted from L.Muche, 2009) 
1. Aβ is produced from amyloid precursor protein (APP). They tend to disrupt space between neurons, 
synapses hindering cell to cell communication 
2. Fibrils of amyloid-β oligomers form plaques. 
3. Inflammatory response to plaques leads microglial cells to release of cytokines that eventually 
lead to neuronal death  
4. Misfolded tau form fibrils inside the neuron that displace intracellular signaling pathways. 














The amyloid cascade hypothesis has dominated the field of AD research for the 
past two decades and is founded on the premise that deposition of Aβ peptide is the 
initiating event in disease pathogenesis, ultimately leading to neurofibrillary tangle 
formation, synaptic loss, and neuronal cell demise (Hardy and Higgins, 1992). For nearly 
two decades, the amyloidogenic processing of APP to form Aβ has been recognized as a 
viable molecular target for AD therapeutic development (Vassar, 2001; Evin et al. 2006). 
The amyloidogenic pathway generates beta amyloid (of which the Aβ1-42 form - here 
referred to simply as Aβ) is commonly regarded as the most likely toxic species) through 
the sequential cleavage of APP by the beta-site APP cleaving enzyme (BACE; also known 
as β -secretase) and γ-secretase. Alternatively, the sequential cleavage of APP by α-
secretase and γ - secretase is considered non-amyloidogenic (Fig. 2) 
Based largely on the amyloid cascade hypothesis (Fig. 3), selective inhibitors of 
BACE and γ -secretase have been developed as drugs to decrease the tissue load of Aβ 
in AD brain (Vassar et al., 2009; D’Onofrio et al. 2012). Unfortunately, amyloid altering 
drugs have resulted in largely disappointing results in the clinic. For instance, two large 
Phase III clinical trials of the γ -secretase inhibitor, semagacestat, in mild-to-moderate AD 
Fig. 2. Distinct pathways of APP proteolytic 
processing. APP processing has two different pathways 
once it has been inserted into a lipid membrane. The non-
amyloidogenic pathway utilizes α-secretase to produce 
soluble amyloid-beta precursor protein-alpha (sAPPα) and 
C-terminal fragment 83 (CTF83). γ-secretase then cleaves 
the CTF83 into a soluble p3 fragment and the amyloid 
precursor protein intracellular domain (AICD). The 
amyoidogenic pathway utilizes processing by β-secretase, 
which produces the soluble amyloid-beta precursor 
protein-beta (sAPPβ) and C-terminal fragment 99 or 89 
(CTF99/89), depending on tissue type. γ-secretase then 
cleaves CTF99/89 into Aβ40 or Aβ42, which become 
extracellular, and the AICD. (Figure adapted from Müller 








patients were terminated early due to a statistically significant worsening of clinical 
measures of cognition and ability to perform activities associated with daily living 
(D’Onofrio et al. 2012). Even more recently, Eli Lilly’s anti-amyloid antibody, solanezumab, 
failed in a Phase III trial of patients with mild-to-moderate AD and a second trial in 
prodromal AD patients was terminated (Mullard A. 2017). The Merck compound, MK-8931 
(verubecestat), is a selective BACE inhibitor that initially completed Phase I testing and 
reportedly was capable of reducing cerebral spinal fluid amyloid levels by up to 90% in 
rats, monkeys, healthy human volunteers, and AD patients (Menting and Claassen, 2014; 
Kennedy M.E. et al. 2016). A Phase II/III clinical trial of this drug (EPOCH) completed 
enrollment in early 2016 in a population of patients with mild-to-moderate AD. 
Unfortunately, in February of 2017, Merck announced that it was terminating the trial after 
an interim analysis suggested little chance of discerning any positive therapeutic benefit 
(Mullard A. 2017). This was a significant setback for the AD field. As a result of these 
recent clinical disappointments, and due to the observation that brain amyloid load does 
not necessarily correlate with the severity of cognitive deficits in AD, some have begun to 
question whether the amyloid cascade hypothesis is entirely sufficient to explain the 
underlying pathogenesis of late onset, sporadic AD (Karran and De Strooper, 2016; 
Swerdlow et al. 2017; Tse and Herrup, 2017). Thus, it is essential to identify novel 





Fig 3. An Illustration of amyloid cascade hypothesis. (Figure adapted from Singh et al. 2016) 
1.04 Extracellular secreted protein: Reelin 
Reelin may be one such novel approach for AD. It is a large secreted glycoprotein 
which plays a key role in patterning and layering of the cerebral cortex and other regions 
of the brain during development (Niu et al. 2004; Beffertt al. 2006; Kim et al. 2015; Bosch 
et al. 2016). Reelin has specific roles in each developmental phase of the central and 
peripheral nervous system. This protein was discovered in 1951 as a spontaneous 
mutation variant in mice which have a typical neurological phenotype of ataxia and 
“reeling” gait that is an inability to move around the cage (Falcon DS, 1951; Lambert de 
Rouvroit and Goffinet, 1998). Through chromosome mapping, the reelin gene was found 
to be present on chromosome 7q22. Later, antibodies were successfully raised against 
reelin which was termed as CR-50 (Cajal-Retzius 50 marker). During prenatal 
development Cajal Retzius (CR) are primary cells in the marginal zone that secrete reelin 
(D’Arcangelo et al. 1997; Ogawa et al. 1995). Failure to form normal cortical plates in the 
cerebrum and cerebellar hypoplasia are distinct pathological characteristics of reeler 






discovered that reelin plays a significant role in neuronal patterning in the pre-
developmental period (Gabriella D'Arcangelo et al.1995). To achieve correct architecture 
of neocotex, reelin acts as a molecular cue for cells to migrate enabling cells to reach in 
their destined target area (Fig 4.). These mutants have a severe anatomic defect where 
all of the layers in the forebrain are disrupted. Shortly after neocortex formation, this 
population of CR cells die. During the postnatal development phase, residual CR cells are 
involved in functions like axonal maturation and dendrite outgrowth which provides 
branching patterns in the brain (Niu et al. 2004; Kupferman et al. 2014). However, in the 
adult brain only a subset of cells, especially GABAergic interneurons found in cortical, 
granular layer and hippocampal regions, secrete reelin, and are thought to be involved in 
synaptic plasticity (Pesold et al. 1998). Therefore, Reelin has myriad roles such as those 
involved in axonal and dendrite outgrowth, synaptogenesis, spine formation, long term 
potentiation in developing and post-development phases (Weeber et al. 2002; Beffert et 
al. 2005). This indicates that it acts on heterogenous cell populations such as glial cells, 
astrocytes, stem cells, newborn and differentiated cells etc. This spatiotemporal regulation 




















Fig 4. Schematic representation of early cortical development in mice and reelin function in 
brain development. A)At embryonic day (E) 13.5 (The preplate stage) neurons colonize maybe 
through somal translocation and form a horizontal trail of cells, as directed by arrows. At this stage 
reeler phenotype is not distinct from wild type. At E14.5 as embryonic plate complexity increases, cells 
migrate along the glial fibers. The cells in fluorescent green condense in cortical plate forming two 
distinct compartments, while in reeler phenotype, same cells are obliquely oriented and does not split 
the preplate into two compartments. At E15.5, a second group of cells (magenta) migrate through the 
cortical plate and settle superficially forming an inside to outside gradient. In reeler mutants, these 
newly formed cohort cells settle in deeper layers of cortex forming an outside to inside gradient. 
(Adapted from Fadel Tissir 2003) 
B)Green squares represent reelin producing cells that are localized in marginal zone (MZ) in 
predevelopment phase. Purple ovals represent neurnal cell bodies from cortical forebrain (CZ) that 
migrate towards MZ. In postnatal development, reelin is involved in axonal and dendritic maturation 




1.05 Structure of Reelin 
Different functional modalities are contributed by distinct structural features of 
reelin. Human full-length reelin protein is approximately 388 KDa and is composed of eight 
repeats (R) (Fig. 5). Each of these repeats surround an epidermal growth factor (EGF) like 
motif. The N-terminus of reelin contains a signal peptide which is structurally like an F-
spondin domain while the C-terminal region is positively charged (D’Arcangelo et 
al.,1997). After secretion, this full-length protein undergoes cleaved by metalloproteases 
at two sites to create three fragments: an N-terminal (Nt=N-R2), a central(C=R3-R6), and 
a C-terminal (Ct=R6-CTR) fragment (Koie et al. 2014; Sato et al. 2016). How each 
fragment or full-length protein is functionally activated and/or regulated is unknown. 
Although the C-terminal fragment alone was enough for the activation of downstream 
signaling pathways and cortical pattering in brain slices. From all collective biochemical 
studies, it seems that fragments of reelin act as regulatory molecules on the full-length 
protein. At the same time, these fragments also activate signaling pathways that are 
distant from their source of origin (Jossin et al. 2007). 
Since its role is fundamental for neuronal processes like synaptic plasticity, its 
deficits in reelin expression can lead to severe debilitation of motor or cognitive functions. 
Several neuropsychiatric disorders such as schizophrenia, autism and depression are 









1.06 Signaling pathway of Reelin 
Reelin is secreted into the extracellular space where it interacts with one of two 
cell surface receptors on target cells, either the very low-density lipoprotein receptor 
(VLDLR) or the apolipoprotein E receptor-2 (ApoER2) (Fig.6). Upon binding its receptor, 
Reelin induces tyrosine phosphorylation of the adapter protein, Disabled-1 (DAB1), via the 
nonreceptor tyrosine kinases, Src or Fyn. Phosphorylated DAB1 acts as a docking site to 
initiate multiple downstream signal transduction cascades such as those involved in cell 
survival (PI3K/AKT) and regulation of actin assembly (Cdc42/PAK/cofilin) (Fig. 1; Wasser 
and Herz, 2017). The pathway described here represents the canonical Reelin signaling 
pathway and is the one most commonly attributed to Reelin’s actions in the central nervous 
system. However, alternative Reelin signaling pathways do exist, as well as additional 
Reelin receptors (Bock and May, 2016; Lee and D’Arcangelo, 2016). 
Figure 5. A schematic illustration of reelin protein and its cleavage fragments. Reelin comprises of N-
terminal (Nt) signal peptide, F-spondin-like-domain (SL), eight reelin repeats. Each repeat has two 
subdomains A and B which is separated by epidermal growth factor (EGF). The full-length protein is cleaved 




1.07 Non-Canonical receptors of Reelin  
Non-canonical pathways refer to Reelin’s interaction with cellular receptors other 
than VLDLR and/or ApoE2, that further lead to activation of Dab1 (Bock, H. H., & May, P. 
2016). The core function of Reelin was realized through its interaction with LDL receptors 
and Fyn-dependent NMDA receptors. NMDA receptors are glutamate receptors that are 
essential for synaptic plasticity and memory formation. Therefore, Reelin was one of the 
extracellular proteins that partakes in LTP by consolidating neuronal synapses. 
Apolioproteins are another class of proteins that interact with LDL receptors. A well-known 
apolipoprotein variant, ApoE4 has been implicated in sporadic AD. Since the Reelin and 
ApoE signaling pathways share a common link with LDL receptors, it has been postulated 
that reelin may be a potential molecule involved in APP processing. It has been shown 
that reelin levels decrease in an AD mouse model and in AD patients. A novel interaction 
between reelin and APP has been demonstrated through several in vivo and in-vitro 
experiments. Overall it was shown that Reelin increases APP receptors on the cell surface 
Fig. 6. Canonical Reelin signaling pathway. Reelin binds to one of two cell surface receptors, VLDLR 
or ApoER2, and induces tyrosine phosphorylation of the adapter protein, Dab1, via Src family kinase 
activity. Phosphory-lated Dab1 acts as a docking site to initiate multiple downstream signaling cascades. 
(Figure adapted from Wasser and Herz 2017).  
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and decreases processing of APP into Aβ peptides. This study also postulates that the 
interactions of Reelin with APP promotes neurite outgrowth in cultured neurons and 
dendrite processing in vivo (Hoe, H. S et al., 2009). 
1.8 Anatomy of hippocampus 
Hippocampus is the region in brain that is predominantly involved with memory 
and learning. It is composed of three primary regions - dentate gyrus, subiculum and 
entorhinal cortex (Fig 7.). The dentate gyrus is further subdivided into three parts that are 
differentiated based on types of cells that populate each part. The molecular layer is a 
cell-free layer and is composed of apical dendrites that branch in from granular cells. The 
intermediate layer of DG is also known as the granular layer and consists of a large 
population of granule cells. Following this layer is the Hilus layer which is distinctively 
composed of mossy cells. The Cornus Ammonis (CA) is the elongated C shaped structure 
which is composed of pyramidal cells. This CA region is also sub-divided into three 
regions, beginning from the region that is at proximity with dentate gyrus, CA3-CA2-CA1 
(Amaral, D; Lavenex P;2006). The entorhinal cortex is typically the first region of the brain 
that is susceptible to plaque deposition and tangle formation in AD. 
The major neuronal connections to the hippocampus are through the entorhinal 
cortex while its major output is through CA1. Neuronal projections in CA1 traverse via two 
main pathways, that are termed as direct and indirect. The direct pathway involves axons 
that originate from layer III in EC and form synapses with distal apical dendrites of CA1. 
The indirect pathway involves axons originating from layer II of EC and finally to CA1 
through the trisynaptic circuit. The initial part of this pathway involves axons from the 
perforant pathway to the granule cells of the dentate gyrus (synapse 1). From there the 
information follows through the mossy fibers to CA3 (synapse 2). CA3 axons 
called Schaffer collaterals exit from the cell body and loop around the apical dendrites by 
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which they connect to CA1 (third synapse). Axons from CA1 then project back to the 
entorhinal cortex, completing the circuit. In addition to the classical trisynaptic circuitry 
where CA3 axons connect with CA1 axons, CA3 axons also form collaterals with other 
CA3 neurons. This recurrent pathway lead to theories of CA3 as forming an auto- 
associative system of memory (Anderson et al.,2000). 
 
Figure 7: Anatomy of hippocampus in mice.  
1.09 Reelin signaling in the entorhinal-hippocampal formation 
Neurons of the entorhinal cortex project to the hippocampus and are involved in 
declarative memory formation and consolidation. Entorhinal cortex layer II neurons 
provide the principal excitatory input to the dentate gyrus of the hippocampus. The 
entorhinal cortex layer II neurons are one of the first neuronal populations to die in AD, 
resulting in a severe loss of synaptic contacts to the dentate gyrus. Many of the entorhinal 
cortex layer II neurons express Reelin and these Reelin-expressing cells are significantly 
reduced in the brains of human amyloid precursor protein (hAPP) transgenic mice 
expressing the Swedish and Indiana mutant form of the hAPP gene (hAPPsweind orJ20 
strain). In accordance with the loss of these Reelin-expressing cells, Reelin levels in the 
Image not drawn to scale 
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hippocampus of J20 mice are also significantly reduced (Chin et al., 2007). Similar loss of 
Reelin-expressing entorhinal cortex layer II neurons is also observed in the brains of 
patients with AD (Chin et al., 2007; Herring, 2012). Finally, in a transgenic rat model of AD 
(McGill-R-Thy1-APP strain), Reelin-expressing neurons of the entorhinal cortex layer II 
were found to selectively express increased levels of soluble intracellular A early in 
disease, prior to the deposition of amyloid plaques (Kobro-Flatmoen, 2016). Collectively, 
these studies suggest that loss of Reelin-expressing cells and their synaptic projections 
to the hippocampus play a central role in the early pathogenic changes in AD (Krstic et 
al., 2013). Moreover, deficiencies in Reelin signaling to the hippocampus likely underlie 
some of the cognitive deficits observed in patients with AD (Cuchillo-Ibañez et al., 2016; 
Yu et al., 2016). Therefore, strategies focused on rescuing the deficit in Reelin expression 
and/or signaling might provide a novel therapeutic approach to treating AD. 
1.10 Modulation of Reelin expression in AD alteration 
As noted above, Reelin-expressing cells of the entorhinal cortex layer II are 
significantly reduced in the hAPPSweInd (J20) transgenic mouse model of AD, coinciding 
with a reduction in Reelin levels in the hippocampus of these mice. Further reducing Reelin 
in these mice by crossing J20 mice with heterozygous reeler mice accelerates amyloid 
plaque formation and tau pathology (Kocherhans, 2010). Conversely, Reelin over-
expression in J20 AD model mice significantly delays amyloid plaque formation and 
rescues cognitive deficits in these mice (Pujadas, 2014). Thus, J20 mice are an 
established model of familial AD and the disease course of these mice is significantly 
impacted by alterations in Reelin, making this an excellent model system to investigate 
the potential therapeutic benefits of modulating Reelin expression. 
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1.11 Oxidative stress 
Oxidative species are free radical molecules that can arise from exogeneous or 
endogenous sources (Kim, G. H. et al., 2015). Some of the exogeneous sources are UV 
radiation, ionizing agents or drugs that have a non-specific mode of action mediated 
through reactive oxygen species (ROS) production (Mani S. 2015). Endogenous sources 
of ROS originate from reactions that occur in mitochondria or other non-mitochondrial 
compartments which are natural by-products of metabolic processes. Some of the 
enzymes that produce free radicals include nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (Nox), xanthine oxidase (XO), nitric oxide synthase (NOS), cytochrome 
P450 from endoplasmic reticulum (ER), and flavin oxidases from peroxisomes (Song P et 
al., 2015). Another source of ROS is through cytokine release from cellular death and 
tissue injury. Immune neutralization reaction is also involved with a release of oxidative 
species; reactions such as Antigen Presenting Cells (APC) that are targeted by immune 
cells. Mitochondrial fission and autophagy are internally programmed mechanism that are 
activated by cellular sensors from factors such as nutritional starvation or signaling cues 
that also contribute to oxidative stress. 
An excessive production of oxidative species or dysfunction in cellular antioxidant 
system leads to oxidative stress which has been linked to aging and neurodegenerative 
diseases. Oxygen tends to form free radicals due to unpaired electrons in its valence shell. 
Therefore, ROS are a group of derivatives from oxygen molecules (Held P. 2012) 
Superoxide radicals (O2•−), hydrogen peroxide (H2O2), hydroxyl radicals (•OH), and 
singlet oxygen (1O2) are some of the examples of oxidative species. Oxygen radicals are 
typically short-lived and highly reactive. Hence, they maybe transformed into a stable form 
such as H2O2 by superoxide dismutase or be protonated to form HO2-. H2O2can further 
decompose to form H2O and O2 via catalase or peroxidases. Hydroxyl ions are one of the 
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most reactive species that have cytotoxic effects on cellular components. Hydroxyl ions 
are also formed from H2O2 and O2 that is catalyzed by Fe ions which are known as 
Fenton’s reaction (Zorov D.B, 2014). 
There are physiological benefits of ROS when maintained at low to moderate 
levels in the cell. Processes such as protein phosphorylation, migration, mitosis, 
differentiation, immune activation takes place under ROS sensor system. To combat a 
higher threshold of toxic oxidative species, cells deploy an antioxidant defensive system 
that are composed of enzymatic components, such as superoxide dismutase (SOD), 
catalase (CAT), and glutathione peroxidase (GPx) which uses glutathione (GSH) to 
detoxify peroxides (Kim G.H., 2015). However, in an aged individual, these antioxidant 
pathways are overwhelmed by ROS. 
1.12 Immunocal®: GSH precursor and modulator of Reelin expression 
Immunocal® is a non-denatured whey protein isolate and a rich source of the 
glutathione (GSH) precursor cysteine. Supplements that only contain cysteine are not 
viable source of glutathione since it is spontaneously catabolized by gastrointestinal tract 
and blood. However, Immunocal® is metabolized in the liver to form cystine which is 
resistant to trypsin proteolysis and can pass through the bloodstream. Cystine is 
transported into neurons via the system xc− antiporter (Sxc−). Cystine is hydrolyzed to 
form two cysteine molecules, which are then utilized in the de novo synthesis of GSH by γ-
glutamylcysteine ligase (γ-GCL) and glutathione synthase (GSS) (Winter et al. 2017). 
Glutathione is a tri-peptide (glutamate, cysteine, glycine) endogenous antioxidant. 
Cysteine and glutamate in presence of enzyme γ-glutamyl synthetase (γ-GCS) forms γ-
glutamylcysteine. Glutathione (GSH) is then synthesized from glycine and γ-
glutamylcysteine in presence of glutathione synthetase (GS). GSH is further oxidized by 
neutralizing various free radicals that are produced within the cell. Through kinetic studies, 
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it has been observed that cysteine is the rate limiting substrate in the synthesis of 
glutathione. Therefore, Immunocal® may be a potential source to increase cysteine that 
could lead to a higher conversation rate to glutathione restoring cellular repair from 
oxidative stress. 
 The ratio of reduced to oxidised glutathione (GSH:GSSG) within cells is used as 
a marker of cellular toxicity. Under normal conditions, this ratio is known to be present in 
mammalian cells in the concentration range of 1–10 mM. However, in a resting cell, the 
molar GSH:GSSG ratio is found to be greater than 100:1, and in various models of 
oxidative stress, this ratio has been observed to decrease considerably (Zitka, O. et al. 
2012). 
 Immunocal® has been shown to boost levels of this essential antioxidant and 
improve muscle strength in certain patient populations, healthy human volunteers, and 
non-frail elderly subjects (Bounous et al. 1991; Grey et al. 2003). It was previously shown 
that incubation with Immunocal® protects primary cerebellar granule neurons and various 
neuronal cell lines from multiple stressors including glutamate, nitric oxide, and A (Winter 
et al., 2017). Moreover, the neuroprotective effects of Immunocal® observed in vitro are 
dependent on the de novo synthesis of GSH. In a similar manner, it was also shown that 
oral treatment of G93A mutant hSOD1 transgenic mice with Immunocal® preserves spinal 
cord GSH and delays disease onset in a mouse model of amyotrophic lateral sclerosis 
(Ross et al. 2014). Finally, in a schizophrenia mouse model characterized by low brain 
GSH and low Reelin levels, Immunocal® was recently shown to elevate both GSH and 
Reelin in the brain (Song et al. 2017). In preliminary studies in the Linseman lab, 
Immunocal® induces Reelin expression in vitro in hippocampal-entorhinal cortex 
organotypic slices and rescues Reelin expression in vivo in J20 AD model mice at 5- 
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months of age. Thus, Immunocal® has the capacity to increase brain GSH and in parallel, 
enhance Reelin expression in both slice culture and mouse models.  
Hypothesis: We hypothesize that oral treatment with the cysteine-rich whey protein 
supplement, Immunocal®, from 3-month-old to 12-month-old will significantly rescue GSH 
levels and Reelin expression in the entorhinal cortex-hippocampus of hAPPsweind mice as 
well as ameliorate amyloid plaque neuropathology in this mouse model of AD. 
1.13 Summary of Major Findings 
We evaluated the effects of Immunocal® treatment in vivo by treating hemizygous 
J20 hAPPsweind AD mice from 3 months-old to 12 months-old. We assessed Reelin 
expression by western blotting and immunofluorescence microscopy. Immunocal® 
treatment corrected a deficit in cortical GSH levels observed in the brains of untreated 
hemizygous J20 mice. Western blotting of brain sections micro-dissected to enrich for the 
hippocampal-entorhinal cortex sub-region revealed a decrease in Reelin expression in 
untreated hemizygous J20 AD mice compared to non-carrier control mice. These deficits 
were corrected by treatment with Immunocal®. In a similar manner, using 
immunofluorescence microscopy, Reelin expression was diminished in the entorhinal 
cortex, dentate gyrus and CA1/CA3 regions of the hippocampus in untreated hemizygous 
J20 AD mice compared to non-carrier control mice. In contrast, Immunocal® treatment 
rescued these deficits in Reelin expression. Since reelin protein is ubiquitously produced 
in all regions of the brain, we analyzed reelin transcripts in hippocampal region of J20 AD 
mice by in situ hybridization. We found that reelin mRNA levels were significantly reduced 
in entorhinal cortex region of hippocampus and this deficit was also rescued by treatment 
with Immunocal®. In parallel with the observed rescue of Reelin expression in the 
hippocampus-entorhinal cortex of J20 mice, Immunocal® also preserved GAD67 
expression in the dentate gyrus and CA3 region of the hippocampus. Perhaps most 
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importantly in the context of AD, we evaluated the deposition of amyloid plaques in the 
J20 mice. These mice have been shown to have significant plaque load at 12-months-old. 
We show that untreated J20 mice do indeed accumulate a significant plaque load in the 
hippocampus and entorhinal cortex. After treatment with Immunocal® the plaque load was 
























Chapter Two: Materials and Methods 
2.01 Reagents 
Immunocal® was provided by Immunotech (Vaudreuil-Dorion, QC, CA). Gey’s 
balanced salt solution and ProLong Gold was purchased from Invitrogen (Carlsbad, CA, 
US). Primary antibodies for Reelin (ab78540), NeuN (ab104225), DRAQ7™, and β-actin 
(ab 115777) were purchased from Abcam (Cambridge, UK). Secondary antibodies for 
immunofluorescence were purchased from Jackson Immunoreserach (Westgrove, PA, 
US). Horseradish peroxidase (HRP) secondary antibodies for Western blotting were 
purchased from Bio-Rad, catalogue no. 1706515 (Hercules, CA, US). All probes 
(RNAscope® Probe Mm-Reln-C3 catalogue no. 319361-C3) and reagents (RNAscope® 
fluorescent multiplex kit, catalogue no.320850) for in situ hybridization were purchased 
from Advanced Cell Diagnostics (Newark, CA, US). Amylo-Glo was purchased from 
Biosensis (Thebarton, SA, AU).  
2.02 Experimental model:  
To investigate the effects of Immunocal® on Reelin expression in vivo, we utilized 
the hAPP(Swe/Ind) mutant transgenic mouse model of AD (J20 strain). This mouse model 
is commercially available from Jackson Laboratories (B6.Cg-Tg(PDGFB-APPSwInd) 
20Lms/2Mmjax) and displays significant brain pathology, amyloid plaques, and cognitive 
deficits that recapitulates multiple aspects of AD in humans (Mucke et al., 2000; Karl et 
al., 2012; Diaz-Hernandez et al., 2012). According to previous reports, these transgenic 
mice typically show significant cognitive deficits, diminished numbers of Reelin-positive, 
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entorhinal cortex (EC) layer II neurons, and decreased Reelin expression in the 
hippocampus by approximately 4-5 months of age. Above, in concordance with the 
literature, we demonstrated that these mice show deficits in GSH, elevated oxidative 
stress, and reduced levels of Reelin protein in the hippocampal-entorhinal cortex formation 
at 5-months of age. As these mice age, amyloid plaques (a hallmark of AD pathology) are 
visible in the brains of these mice by around 12-months of age. All animal studies were 
conducted in accordance with a protocol approved by the University of Denver Institutional 
Animal Care and Use Committee. 
2.03 Immunocal® treatment: 
To address this experimental question required three groups of mice: 
hAPP(Swe/Ind) mutant hemizygous mice (J20 strain) treated with Immunocal® (3.3% w/v 
in drinking water ad libitum, as previously described by Ross et al., 2014), untreated 
hemizygous J20 mice, and untreated non-transgenic (non-carrier) control mice. 
Immunocal® treatment was initiated at 3-months-old and continued until the mice were 
12-months-old.  
2.04 Analysis of brain GSH and GSSG by HPLC with electrochemical detection 
(HPLC-ECD) 
2.041 Tissue processing: 
Cortical tissue was obtained from mice and immediately frozen in liquid nitrogen. 
For HPLC-ECD analysis, 2.5M perchloric acid was added and the brains were roughly 
chopped using pointed surgical scissors. Samples were then sonicated 3 times for 15s 
intervals. Samples were then centrifuged for 5min at 13,000rpm and the supernatant was 
removed. A 20µL aliquot of the supernatant was used for a BCA protein assay. The 
remainder of each solution was neutralized with 500µL of 4M KOH and vortexed 
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thoroughly. Samples were then centrifuged for 15min at 13,000rpm, and stored at -80°C 
until separation and analysis by HPLC-ECD. 
2.042 HPLC-ECD: 
GSH in samples and known standards were separated by reversed-phase HPLC 
on a C18 bonded silica column at 35°C (5µm, 4.6mm x 25cm) from Tosoh Bioscience. 
(Grove City, OH, US). Analytes were detected using a CoulArray® detector (model 5600, 
ESA) on three coulometric array cells in series; electrochemical detectors were set 
between 0 and 900mV at increments of 75mV. Concentrations were determined with a 
standard curve of each identified analyte. Mobile phase consisted of 50mM lithium acetate 
and 1% acetonitrile in water, pH 3.8. The flow rate was set to 0.4mL/min for all samples. 
CoulArray® software was used for baseline correction and peak analysis. 
2.05 Western Blotting 
Mice brain was rapidly dissected where one hemisphere was placed into ice cold 
Gey’s balanced salt solution for slicing while the other half was flash frozen in liquid 
nitrogen and stored at -800C. Briefly, the flash frozen half were thawed, then brain slices 
were lysed using a Dounce homogenizer and Wahl lysis buffer supplemented with 
aprotinin and leupeptin. The samples were diluted 1:100 for a BCA protein assay. Western 
immunoblotting was done to immunochemically detect proteins immobilized on 
polyvinylidene difluoride (PVDF) membranes. Protein samples (50 µg/lane) were resolved 
by SDS-PAGE and proteins were then transferred to PVDF membranes. Non-specific 
binding sites were blocked using 1% BSA in PBS (pH 7.4) containing 0.1% Tween-20 
(PBS-T) for 1 h at 25°C. The blocking buffer was drained, and the membrane was allowed 
to incubate in primary Reelin antibody (1:1000) diluted in blocking buffer overnight at 4 °C. 
The membrane was washed 3 times for 15min in PBS-T. Immunoreactive proteins were 
detected using enhanced chemiluminescence (GE Healthcare; Pittsburgh, PA) and films 
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were developed using a ChemiDoc developer (BioRad, Hercules, CA). Re-probing of blots 
was performed by stripping in 0.1 M Tris-HCl (pH 8.0), 2% SDS, and 100 mM β-
mercaptoethanol for 30min at 52 °C. The blots were rinsed twice in PBS-T and processed 
as above with a different primary antibody. Relative intensities of the protein bands were 
quantified by scanning densitometry using ImageJ. 
2.06 Insitu mRNA Hybridization 
Samples were processed according to ACD RNAscope Fluorescent Multiplex 
Assay manual (Newark, CA, US). Using a vibratome (Leica), brain tissue was freshly 
sliced in ice cold Gey’s balanced salt solution at (roughly 500 µM thickness) such that the 
hippocampal entorhinal cortex region was preserved, then the slices were embedded in 
OCT and frozen in liquid nitrogen. Brains were then sliced at 30µm thickness with a 
cryostat (Leica CM 1950) and adhered onto SuperFrost Plus Slides and stored at -800C 
until use. Sliced tissues were permeabilized using 4% paraformaldehyde (PFA) and 
incubated for 15min. Slides were rinsed twice with 1X PBS (pH 7.4) buffer. Tissues were 
dehydrated consecutively in 50%, 70% and 100% ethanol for 2min each. A barrier was 
created around the tissue using a hydrophobic pen. Tissues were then incubated in 
protease inhibitor for 30min at 25°C in HybEZ™ Humidity Control Tray. About 4-6 drops 
of Reelin or NeuN (positive control) probe was added to tissues. The slides were inserted 
in slide holder and placed in HybEZ™ Humidity Control Tray and incubated for 2h at 400C 
in HybEZ™ Oven. After washing in 1X PBS buffer, samples were hybridized by adding 4-
6 drops with Amp1, Amp2 and Amp3 for 30, 15, 30min respectively at 400C. Samples were 





2.07 Immunofluorescence  
Using a vibratome (Leica), brain tissue was freshly sliced in ice cold Gey’s 
balanced salt solution at (200µM thickness) such that the hippocampal entorhinal cortex 
region was preserved, then was added to a 6-well plate (1 slice/well) containing ice cold 
4% PFA  and fixed for 90min. Fixative was removed from the wells and the slices were 
washed three times for 5min in PBS-T. After the final wash, PBS-T was removed and 1ml 
of Blocking Solution (5% BSA, 1× PBS, 0.05% Tween-20, pH 7.4) was added to the wells 
and incubated at  25°C for 90min. Blocking solution was replaced with primary antibody in 
blocking solution at the specified dilutions. (Table 1) and incubated overnight at 40C. The 
following day, primary antibody was removed, and the tissue was washed 3 times for 5min 
in PBS-T. Slices were then incubated with the secondary antibody diluted in blocking 
solution at the indicated concentrations for 90min at  25°C. Then, secondary antibody 
solution was removed and immediately replaced with 1ml of DRAQ7™ diluted in PBS-T 
and incubated for 20min at  25°C. The tissue was carefully transferred to a glass slide 
SuperFrost Plus Slide and excess PBS-T was removed using a Kimwipe Prolong Gold 














Table 1: Antibody concentration and stains 
Primary Antibody Host Dilution 
Reelin (RELN)  Monoclonal mouse anti 
reelin 
1:1000 
GAD67 Monoclonal mouse anti 
GAD67 
1:1000 
NeuN Rabbit polyclonal anti 
NeunN 
1:1000 
   











depending on the 
primary 
1:5000 
HRP conjugated Goat anti-mouse HRP 1:5000 
Stains   
DRAQ7™ Nuclear specific stain 1:1000 
Amylo-Glo® Aβ plaque specific stain 1:100 
 
2.08 Quantification of reelin staining and amyloid plaques 
Images were collected using Olympus FLUOVIEW FV3000 confocal laser 
scanning microscopy using an Olympus 20X PLN objective. Confocal z-series were 
captured at same exposure times across all samples (n=4 to 5 in each group for protein 
staining and n=3 in in situ hybridization). Each region of hippocampus (EC, DG, CA3/CA1) 
was captured in triplicates. Total fluorescent intensity was analyzed in Adobe Photoshop 
for protein staining and in situ hybridization. Any adjustments made in the analysis step 
was accounted constant for all the groups. 
For amyloid quantification by image J software, the color images were converted 
in to HSV format and 8-bit channels. Plaques were quantified in an unbiased manner by 
an investigator blind to the treatment nature of the samples. Plaque number was 
calculated from each area of hippocampus whereas plaque load was calculated as the 
area occupied by the plaques divided by the total brain region area.  
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2.09 Statistical analysis 
All the data collected were analyzed with GraphPad Prism 5 software using one-
way analysis of variance (ANOVA) followed by a post-hoc Tukey’s test. Descriptive 
statistics were displayed as an expressed mean ± S.E.M. Quantitative differences were 
























Chapter Three: Results 
3.01 Glutathione Analysis 
We measured the brain levels of reduced glutathione (GSH) and oxidized 
glutathione disulfide (GSSG) in cortical tissue from the mice using HPLC-ECD. Untreated 
hemizygous J20 mice displayed a reduction in cortical GSH and a dramatic increase in 
GSSG at 12-months-old when compared to non-carrier control mice (Fig. 8 A, B). 
Hemizygous J20 mice treated with Immunocal® showed a complete preservation of 
cortical GSH and a reduction in GSSG, both of which were statistically significantly 
different from the levels observed in untreated hemizygous mice (Fig. 8 A, B). 
Furthermore, the GSH/GSSG ratio, a key measure of oxidative stress, showed a 
statistically significant reduction in the untreated hemizygous mice when compared to the 
non-carrier control mice (Fig. 8 C). This indicates increased oxidative stress in the brain 
of J20 AD mice. This effect was completely prevented by treatment with Immunocal® from 
3-months-old to 12-months-old (Fig. 8C). Therefore, Immunocal® treatment corrects a 
deficit in brain GSH, reduces levels of GSSG, and diminishes the abnormal levels of 

























Fig. 8. Immunocal® treatment preserves brain GSH in J20 AD model mice. Brain (cortical) tissue was harvested 
from 12-month-old hemizygous J20 AD mice (either untreated (Unt) or treated with Immunocal® (ICAL) for 2 months 
and non-carrier control mice. Tissue was extracted and reduced GSH and glutathione disulfide (GSSG) were measured 
by HPLC with electrochemical detection. Values are normalized to protein content represented as mean±SEM for n=3 
mice per group. Statistical differences were calculated by one-way ANOVA with a post hoc Tukey’s test. ns=not 




3.02 In situ mRNA Hybridization for reelin transcript 
We used in situ hybridization technique to analyze regions of hippocampus that 
express reelin transcripts. Entorhinal cortex (EC) is a primary region in hippocampus to 
produce reelin. Along with EC, interneurons also synthesize reelin in the CA3 region. In 
this study, we found mRNA expression for reelin mostly concentrated in the regions of 
hilus layer in dentate gyrus, CA3 and entorhinal cortex of hippocampus. We compared 
regions of entorhinal cortex and CA3 of non-carrier with hemizygous untreated and 
Immunocal® J20 mice. There was a significant decrease in reelin transcript levels 
detected in CA3 and EC regions of hemizygous untreated mice when compared to non-
carrier. Immunocal® treatment significantly preserved reelin transcript expression only in 
the EC (Fig. 9 A,B). 
 
    


















Fig. 9. Immunocal® treatment increases Reelin mRNA expression in hippocampal-entorhinal 
cortex slices. (A) Brain tissue was harvested from 12-month-old hemizygous (Hemi) J20 AD mice 
(either untreated (Unt) or treated with Immunocal® (ICAL) for 9 months) and non-carrier control 
mice. Formalin-fixed sections were hybridized with anti-sense Reelin transcript (Rln, shown in 
green) along with Draq (nuclear stain, shown in blue).  Scale bar = 250µm 
(B) The graph indicates total fluorescent intensities for (n = 3) mice in CA3 and EC region of 
hippocampus. Reelin was significantly decreased in CA3 and EC in untreated hemizygous mice 
compared to non-transgenic controls. ICAL treatment significantly preserved Reelin staining in the 
hemizygous mice only in EC. Statistical differences were calculated by one-way ANOVA with a post 
hoc Tukey’s test.  
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3.03 Analysis of Reelin Expression – Western Blotting 
We next evaluated the expression of Reelin protein in the 12-month-old J20 AD 
mice by western blotting brain tissues enriched for the hippocampal-entorhinal cortex 
formation. Reelin expression was significantly reduced in untreated hemizygous J20 AD 
mice compared to non-carrier controls and Immunocal® treatment largely corrected this 
deficiency (Fig. 10A). The Reelin blots were stripped and re-probed for beta-actin as a 
loading control. We detected the 180 kDa cleavage fragment of Reelin in these mouse 
brain lysates. Quantitative densitometric analysis of the 180 kDa Reelin band (normalized 
to β-actin) revealed an approximate 30% reduction in Reelin protein expression in 
hemizygous untreated AD mice compared to non-carrier controls, and a complete 
preservation of Reelin expression in Immunocal®-treated mice (Fig. 10B). In concordance 
with the literature, we show a reduction in the Reelin protein levels by western blot in 12-
month-old J20 AD mice. We also show that treatment with Immunocal® rescues this 










                                                          
 
3.04 Analysis of Reelin Expression – IHC 
We then used IHC and immunofluorescence microscopy technique to evaluate 
eelin expression in the entorhinal cortex, dentate gyrus, and CA1/CA3 regions of the 
hippocampus in 12-month-old J20 AD model mice. In comparison to the non-carrier 
control, untreated hemizygous J20 AD mice displayed a significant reduction in Reelin 
immunoreactivity in all the regions of hippocampus. Intriguingly, treatment with 
Immunocal® from 3 months-old to 12 months-old largely rescued this deficit in Reelin 
expression within dentate gyrus and entorhinal cortex region of J20 AD mice (Fig. 11 A-
D). 
Fig 10. Immunocal® treatment rescues Reelin expression by western blotting in J20 AD model mice. Brain 
tissue was harvested from 12-month-old hemizygous (Hemi) J20 AD mice (either untreated (Unt) or treated with 
Immunocal® (ICAL) for 9 months) and non-carrier control mice. Tissue was micro-dissected to enrich for the 
hippocampal-entorhinal cortex sub-region. (A) Brain lysates were resolved by SDS-PAGE and immunoblotted for 
Reelin. The Reelin blot was stripped and re-probed for beta-actin. (B) The graph shows the densitometric analysis of 
the 180 kDa Reelin bands normalized to the beta-actin bands in arbitrary units (n=3 mice per group). Statistical 








Fig 11. Immunocal® treatment rescues Reelin expression by Immunohistochemistry in J20 AD model 
mice. Brain tissue was harvested from 12-month-old hemizygous (Hemi) J20 AD mice (either untreated (Unt) or 
treated with Immunocal® (ICAL) for 9 months) and non-carrier control mice. Formalin-fixed sections were co-
stained with antibodies to Reelin (Rln, shown in green) and NeuN (shown in red), along with Draq (nuclear stain, 
shown in blue). Scale bar = 250µm 
The graph indicates total fluorescent intensities for (n = 4-5) mice in each region of the hippocampus. Reelin 
was significantly decreased in (A)EC, (B)DG, (C)CA1, and (D)CA3 in untreated hemizygous mice compared to 
non-transgenic controls. In the EC and DG, ICAL treatment significantly preserved Reelin staining in the 
hemizygous mice. Statistical differences were calculated by one-way ANOVA with a post hoc Tukey’s test. 
35 
3.05 Analysis of Amyloid plaque load 
The J20 mice have been shown to have extensive amyloid-beta plaque loads in 
the hippocampal entorhinal cortex formation by 12-months of age. To evaluate the effects 
of Immunocal® treatment on the deposition of amyloid plaques we used Amylo-glo, an 
amyloid peptide aggregate-specific stain used to mark amyloid plaques. After treating the 
mice from 3-months-old to 12-months-old with Immunocal® there was a dramatic 
reduction in the amyloid plaque load in the hippocampal entorhinal cortex formation of the 
J20 mice (Fig. 12).  In the dentate gyrus, CA3 and CA1 hippocampal regions of untreated 
J20 mice there was a significant plaque load throughout with distinct dense formations 
(Fig. 12). After treatment with Immunocal® for 9-months, this plaque load was greatly 
diminished in the hippocampus and the plaques that are visible are much smaller in 
diameter and density (Fig. 12). When we evaluated the entorhinal cortex of untreated J20 
mice we show a similar number of plaques, however a reduced size and density of 
amyloid-beta plaques relative to the hippocampus. The Immunocal® treated mice have 
diminished size and density of amyloid plaques in the entorhinal cortex (Fig. 12). We 
quantified the total plaque number and total plaque load (plaques/area) and show 
significant reductions in all areas of the hippocampus and entorhinal cortex, with the 
exceptions of CA3 which shows a trend towards significance (Fig. 13 A, B). These data 
show the ability of Immunocal® treatment to suppress and delay the formation of amyloid 
























Fig 12. Immunocal® treatment reduces amyloid-beta plaque load in the hippocampal-entorhinal 
cortex of J20 AD model mice. Brain tissue was harvested from 12-month-old hemizygous (Hemi) J20 
AD mice (either untreated (Unt) or treated with Immunocal® (ICAL) for 9 months). Formalin-fixed sections 
were co-stained with Amylo-glo (amyloid peptide aggregates) in green along with Draq (nuclear stain, 






Fig 13. Quantification of amyloid plaque number and plaque load (A) amyloid 
plaque load (number of plaques/area) (B) for distinct regions of the hippocampus 
(dentate gyrus, CA3, CA1) and entorhinal cortex. Data expressed as meanSEM, dots 








Chapter Four: Discussion 
Reelin is a secretory glycoprotein that plays a role in the maintenance and 
regulation of LTP in neuronal synapses. Its sets a foundation for neuronal cells to be 
placed in right areas of the brain and continues to play a role in brain development through 
the lifetime of an individual. Therefore, its deficit can lead to severe debilitation of motor 
functions that finally affect involuntary activity. Addressing all the functions of reelin, 
especially those that are imperative in consolidation of neural network, we used cysteine-
rich whey protein, Immunocal® for a fixed amount of time period and checked for 
resurgence/rescue of reelin in AD mouse model. Previous studies showed that 
Immunocal® elevate glutathione in the brain and spinal cord which acts as a 
neuroprotective agent from oxidative stress. This potential nutraceutical has been tested 
as a therapeutic source for schizophrenia and ALS mouse model (Ross et al., 2014; Song 
et al., 2017). From this study it was shown that, Immunocal® rescued reelin at the 
transcript and protein level in the prefrontal cortex of mouse model of schizophrenia. 
However, in AD patients, it is known that neuronal population of reelin secretory cells of 
Entorhinal cortex is most vulnerable to neurodegeneration. Therefore, we designed the 
experiment to first observe the site of synthesis in hippocampal region of mouse brains in 
the wild type and AD model. Consequently, we sought to evaluate the effects of 
Immunocal® on Reelin expression and signaling in vitro in hippocampal-entorhinal cortex 
rat brain slices and in vivo in the hAPPSweInd mutant (J20) mouse model of AD.  Previous 
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work has shown that deficits in Reelin expression and/or Reelin signaling play a 
pathogenic role in several nervous system disorders including schizophrenia and AD. 
Thus, strategies aimed at correcting these deficits might provide a novel therapeutic 
approach to these devastating diseases. The cysteine-rich, whey protein supplement, 
Immunocal®, has previously been shown to elevate glutathione in the brain and spinal 
cord and is neuroprotective and therapeutically efficacious in mouse models of 
schizophrenia and amyotrophic lateral sclerosis (Ross et al., 2014; Song et al., 2017). 
Most recently, Immunocal® treatment has been shown to rescue Reelin expression at the 
mRNA and protein level in the prefrontal cortex of a mouse model of schizophrenia (Song 
et al., 2017). Given that Reelin expressing neurons of the entorhinal cortex layer II are a 
highly vulnerable population of cells that are lost very early in AD, we sought to evaluate 
the effects of Immunocal® on Reelin expression and signaling in vitro in hippocampal-
entorhinal cortex rat brain slices and in vivo in the hAPPSweInd mutant (J20) mouse model 
of AD.  
We evaluated the effects of Immunocal® treatment in vivo by treating hemizygous 
J20 AD mice from 3 months-old to 12 months-old. We assessed Reelin expression and 
signaling by western blotting and immunofluorescence microscopy. Immunocal® 
treatment corrected a deficit in cortical GSH levels observed in the brains of untreated 
hemizygous J20 mice. Western blotting of brain sections micro-dissected to enrich for the 
hippocampal-entorhinal cortex sub-region revealed a decrease in Reelin expression in 
untreated hemizygous J20 AD mice compared to non-carrier control mice. These deficits 
were corrected by treatment with Immunocal®. We evaluated Reelin transcript levels in 
hippocampal region of brain by in situ hybridization and quantified transcript levels by 
measuring total fluorescence intensity.  
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 In order to probe for hippocampal specific regions of reelin expression, we used 
immunofluorescence microscopy technique. Reelin expression was diminished in the 
entorhinal cortex, dentate gyrus and CA1/CA3 regions of the hippocampus in untreated 
hemizygous J20 AD mice compared to non-carrier control mice. In contrast, Immunocal® 
treatment largely rescued these deficits in Reelin expression and in entorhinal cortex and 
dentate gyrus significantly. Since reelin is a secreted glycoprotein, it was observed to be 
present in all regions of hippocampus as seen in non-carrier mice. Therefore, we used 
insitu mRNA hybridization technique to investigate specific regions of hippocampus that 
synthesize reelin transcripts. Entorhinal cortex, CA3 and dentate gyrus of hippocampus 
were the only regions that expressed reelin transcripts. Due to tissue integrity being lost 
during slicing procedure in dentate gyrus, we assessed transcript levels only in CA3 and 
entorhinal cortex. There was a significant reduction in transcript expression in 
heterozygous untreated sample when compared with non-carrier. However, there was a 
significant rescue in mRNA levels in entorhinal region of Immunocal® treated sample. We 
suspect that entorhinal region may be involved in production of reelin through which other 
regions of hippocampal receive signal from trisynaptic pathway that is involved in long 
term potentiation. 
Perhaps most importantly in the context of AD, we evaluated the deposition of 
amyloid plaques in the J20 mice. These mice have been shown to have significant plaque 
load at 12-month-old. We have shown that untreated J20 mice do indeed accumulate a 
significant plaque load in the hippocampus and entorhinal cortex. After treatment with 









Chapter Five: Future direction and potential mechanism 
           The mice model used in this study only forms one of the pathological characteristics 
of Alzheimer’s disease that is, Aβ plaques. In order to capitulate complete disease state, 
it would be interesting to use a mice model that also forms tangle pathology such as those 
seen in 3XTg-AD. Using this model may provide cues to reelin downstream signaling 
pathway. We would also like to probe for inflammatory response which could serve as an 
indicative of oxidative stress and cell injury in J20 as well as 3XTg-AD model by staining 
for microglial and astrocyte markers.  
Based on these preliminary results, we have postulated a mechanism that may work 
towards reduction of pathological characteristics in AD. If Immunocal® treatment is 
initiated early-on, it increases glutathione levels in neuronal cells which decreases the 
excessive reactive oxidative species (ROS) generated through aging process. In a 
preliminary study from our lab, Immunocal® treatment was tested from 3-month old to 5-
month old mice. In one of the experiments, we used transcription regulator p-CREB to test 
modulation of reelin synthesis. This transcriptional element is found upstream of reelin 
gene and maybe repressed under oxidative stress condition. We performed western 
blotting to observe p-CREB levels in control, untreated hemizygous J20 mice model and 
treated J20 mice model. The untreated hemizygous J20 AD mice displayed a marked 
reduction in p-CREB immunoreactivity in the hippocampal-entorhinal cortex sub-region of 
the brain and this deficit was essentially rescued by treatment with Immunocal®. With this 
we postulate that p-CREB maybe involved in activation of reelin levels in the cell. 
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Therefore, reelin levels increase in response to an increase in glutathione levels. As 
documented in this study, augmentation of reelin can decrease pathological effects in AD 
such as Aβ plaques and tau fibrils.  
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AD: Alzheimer’s disease  
AKT: Protein kinase B also known as AKT 
APC: Antigen presenting Cell 
ApoER2: Apolipoprotein E receptor-2 
APP: Amyloid precursor protein 
hAPP: human Amyloid precursor protein 
ANOVA: Analysis of variance  
BACE: β secretase 
BCA: Bicinchoninic acid assay 
BSA: Bovine serum albumin 
CDC: cell cycle division 
CA: Cornus Ammonis 
CAT: catalase  
CR: Cajal Retzius 
Ct: C-terminal 
Cy3: Cyanine-3 conjugated 
DAB1: Disabled-1 
DG: Dentate gyrus 
EC: Entorhinal cortex 
ER: Endoplasmic reticulum 
FITC: Fluorescein Isothiocyanate conjugated 
Fyn: Proto-oncogene tyrosine-protein kinase fyn 
GABA: gamma-aminobutyric acid  
γ -GCS: γ-glutamyl synthetase 
GAD: Glutamate decarboxylase 
GS: Glutathione synthetase  
GPx: Glutathione peroxidase 
GSH: Glutathione 
GSSG: Glutathione disulphide 
HPLC-ECD: High performance liquid chromatography and electro-chemical detection 
HRP: Horseshoe radish peroxide 
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KOH: Potassium hydroxide 
LTP: Long term potentiation 
PAK: Serine/threonine-protein kinase 
PBS: Phosphate buffered solution 
PFA: Para formaldehyde  
PI3k: Phosphoinositide 3-kinase 
PS1: presenilin 1 
PS2: presenilin 2 
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NADPH: Nicotinamide adenine dinucleotide phosphate 
Nox: NADPH oxidase  
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SDS-PAGE: Sodium dodecyl sulfate-Polyacrylamide gel electrophoresis 
S.E.M. : Standard error of the mean 
SOD: Superoxide dismutase  
Src: Proto-oncogene tyrosine-protein kinase src 
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